60.14
-0.46 (-0.76%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Cytokinetics, Incorporated | Bearish | - |
Stockmoo Score
|
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 106.00 (Oppenheimer, 76.26%) | Buy |
| Median | 75.00 (24.71%) | |
| Low | 60.00 (B of A Securities, -0.23%) | Hold |
| Average | 79.80 (32.69%) | |
| Total | 9 Buy, 1 Hold | |
| Avg. Price @ Call | 51.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 24 Jun 2024 | 65.00 (8.08%) | Buy | 53.90 |
| HC Wainwright & Co. | 17 Jun 2024 | 90.00 (49.65%) | Buy | 52.78 |
| 23 May 2024 | 90.00 (49.65%) | Buy | 48.98 | |
| B. Riley Securities | 04 Jun 2024 | 92.00 (52.98%) | Buy | 48.41 |
| JMP Securities | 31 May 2024 | 78.00 (29.70%) | Buy | 48.51 |
| 28 May 2024 | 78.00 (29.70%) | Buy | 48.21 | |
| Truist Securities | 29 May 2024 | 70.00 (16.40%) | Buy | 47.86 |
| B of A Securities | 23 May 2024 | 60.00 (-0.23%) | Hold | 48.98 |
| 14 May 2024 | 70.00 (16.40%) | Hold | 59.36 | |
| Barclays | 23 May 2024 | 95.00 (57.96%) | Buy | 48.98 |
| Needham | 23 May 2024 | 72.00 (19.72%) | Buy | 48.98 |
| 14 May 2024 | 108.00 (79.58%) | Buy | 59.36 | |
| Raymond James | 23 May 2024 | 70.00 (16.40%) | Buy | 48.98 |
| Oppenheimer | 09 May 2024 | 106.00 (76.26%) | Buy | 64.02 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MALIK FADY IBRAHAM | - | 57.38 | -7,300 | -418,874 |
| PARSHALL B LYNNE | - | 57.39 | -5,000 | -286,950 |
| Aggregate Net Quantity | -12,300 | |||
| Aggregate Net Value ($) | -705,824 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 57.39 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MALIK FADY IBRAHAM | Officer | 23 Jul 2024 | Sell (-) | 7,300 | 57.38 | 418,874 |
| MALIK FADY IBRAHAM | Officer | 23 Jul 2024 | Option execute | 5,300 | - | - |
| PARSHALL B LYNNE | Director | 15 Jul 2024 | Sell (-) | 5,000 | 57.39 | 286,950 |
| PARSHALL B LYNNE | Director | 15 Jul 2024 | Option execute | 5,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |